Predictive criteria of insignificant prostate cancer: What is the correspondence of linear extent to percentage of cancer in a single core? - Abstract

OBJECTIVE: The aim of active surveillance of early prostate cancer is to individualize therapy by selecting for curative treatment only patients with significant cancer.

Epstein's criteria for prediction of clinically insignificant cancer in surgical specimens are widely used. Epstein's criterion ″no single core with >50% cancer" has no correspondence in linear extent. The aim of this study is to find a possible correspondence.

MATERIALS AND METHODS: From a total of 401 consecutive patients submitted to radical prostatectomy, 17 (4.2%) met criteria for insignificant cancer in the surgical specimen. The clinicopathologic findings in the correspondent biopsies were compared with Epstein's criteria for insignificant cancer. Cancer in a single core was evaluated in percentage as well as linear extent in mm.

RESULTS: Comparing the clinicopathologic findings with Epstein's criteria predictive of insignificant cancer, there was 100% concordance for clinical stage T1c, no Gleason pattern 4 or 5, ≤ 2 cores with cancer, and no single core with >50% cancer. However, only 25% had density ≤ 0.15. The mean, median and range of the maximum length of cancer in a single core in mm were 1.19, 1, and 0.5-2.5, respectively. Additionally, the mean, median, and range of length of cancer in all cores in mm were 1.47, 1.5, and 0.5-3, respectively.

CONCLUSION: To pathologists that use Epstein's criteria predictive of insignificant cancer and measure linear extent in mm, our study favors that ″no single core with >50% cancer″ may correspond to >2.5 mm in linear extent.

Written by:
Billis A, Quintal MM, Freitas LL, Costa LB, Ferreira U.   Are you the author?
Department of Anatomic Pathology, School of Medical Sciences, State University of Campinas (Unicamp), Campinas, Brazil; Department of Urology (UF), School of Medical Sciences, State University of Campinas (Unicamp), Campinas, Brazil.


Reference: Int Braz J Urol. 2015 Mar-Apr;41(2):367-72.
doi: 10.1590/S1677-5538.IBJU.2015.02.26

PubMed Abstract
PMID: 26005981 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.